Hybrid therapy for atrial fibrillation
|
|
- Sandra Clarke
- 7 years ago
- Views:
Transcription
1 European Heart Journal Supplements (2003) 5 (Supplement H), H51 H55 Hybrid therapy for atrial fibrillation C. Wolpert, K.K. Haase, T. Süselbeck and M. Borggrefe Department of Medicine, University Clinic of Mannheim, Faculty of Medicine of the University of Heidelberg, Heidelberg, Germany KEYWORDS Ablation; Drugs; Hybrid therapy; Pacemaker Introduction Atrial fibrillation (AF) is the most common supraventricular arrhythmia, especially in the elderly, and has an important impact on morbidity, quality of life and health care costs. Furthermore, it is associated with an increased risk for arterial embolism, often leading to a significant degree of disability. The predominant therapies for patients with AF in its paroxysmal, persistent and permanent form are still antiarrhythmic drugs and electrical cardioversion. However, new approaches such as preventative pacing, the atrial defibrillator and focal or linear catheter ablation have been developed for a subgroup of patients, depending on the mechanism of AF initiation or refractoriness to drug therapy. Most of these therapies are still used as an adjunct and do not render drug treatment obsolete. The concomitant use of drugs and pacing or ablation has recently been named hybrid treatment. Primarily, Correspondence: Christian Wolpert, MD, Department of Medicine-Cardiology, University Clinic of Mannheim, Faculty of Medicine of the University of Heidelberg, Theodor-Kutzer-Ufer, Mannheim, Germany In some patients with atrial fibrillation stand-alone therapy with drugs, pacemaker or catheter ablation is not able to sufficiently suppress recurrences. Therefore, combined use of either strategies has been introduced using two or more therapeutic approaches in order to augment clinical benefit. Among these, the simultaneous use of antiarrhythmic agents and ablation has been shown to improve the atrial fibrillation burden by promotion of atrial fibrillation to atrial flutter with drugs and consecutive isthmus ablation. Other studies using preventive pacing could document a significant improvement of symptoms and AF burden with additional drugs The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved this term indicates the combined use of, for example, bi-atrial or bifocal pacing and antiarrhythmic agents, or focal pulmonary vein ablation and drugs. The only true conceptional hybrid approach, however, is the modification of AF to atrial flutter with isthmus dependency and the subsequent ablation of the inferior right isthmus to reduce the incidence of AF (Fig. 1). Class IC drug-induced atrial flutter in patients with atrial fibrillation The concept of treating patients with AF by linear ablation of the inferior isthmus and a class IC drug was developed following observations in patients who received propafenone or flecainide intravenously and converted to atrial flutter with isthmus dependency, proven by right and left atrial activation mapping and entrainment pacing. 1 Furthermore, patients treated permanently with oral propafenone or flecainide presented with typical atrial flutter as a subsequent arrhythmia recurrence. This led to systematic testing of patients in AF by several working groups X/03/0H $35.00/ The European Society of Cardiology, Published by Elsevier Science Ltd. All rights reserved.
2 H52 Oral or intravenous class IC drug Linear isthmus ablation Atrial fibrillation Typical atrial flutter Reduced incidence of atrial fibrillation Fig. 1 Concept of hybrid therapy for atrial fibrillation. After promotion of atrial fibrillation to isthmus-dependent atrial flutter, linear inferior isthmus ablation is performed to convert to sinus rhythm. (i.e. studying intravenous administration of a class IC drug during AF). The investigators reported varying percentages of responders. The concept behind this treatment is the hypothesis that, by using class IC drugs, transversal conduction blocks the crista terminalis, and the slowing of isthmus conduction and the change in wavelength of fibrillation cycles lead to an inability to maintain fibrillation. Numerous authors have consistently shown both conduction through the crista terminalis and complete conduction block after the use of, for example, disopyramide (Fig. 2). According to the literature, approximately 5 20% of patients are responders to propafenone or flecainide and convert to atrial flutter. However, there are still no large, prospective investigations that have used continuous Holter or loop recording to ensure reliable information on the true rate or character of arrhythmia recurrence after treatment with a class IC drug for AF. Schumacher et al. 1 reported on a series of 187 patients from an AF registry who were treated with either oral flecainide or propafenone. Of these patients, 12.8% developed atrial flutter during follow-up. Electrophysiological study then revealed typical atrial flutter in 20 patients (10.7%). All patients underwent right atrial linear isthmus ablation. The rate of recurrence of atrial flutter or AF was assessed with a serial questionnaire and Holter recordings. During a mean followup of 11 ± 4 months, the group treated with ablation and a class IC drug exhibited a significantly lower rate of recurrence of AF than that in the group of patients who were treated with an antiarrhythmic drug alone, or in comparison with the rate of recurrence before therapy. These findings were supported by Nabar et al., 2 who studied the effect of additional isthmus ablation for atrial flutter in 24 consecutive patients presenting with AF who developed atrial flutter after intravenous administration of C. Wolpert et al. propafenone or flecainide. In these patients, 54% had typical atrial flutter, eight patients had atypical atrial flutter and three patients had coarse AF. Acute bidirectional block during the ablation procedure could be achieved in 23 of the 24 patients. During a mean follow-up of 13 months (6 26 months), improved control of AF was present in 11 of the 13 patients with typical atrial flutter and in four of the eight patients with atypical atrial flutter during initial propafenone or flecainide administration. It is interesting that the difference in clinical success between the two groups was not statistically significant. In a larger study conducted in 82 consecutive patients, Nabar et al. 3 studied patients with documented typical atrial flutter with or without concomitant AF. In their series, linear isthmus ablation was performed in all patients. The clinical success was assessed for four different groups: patients with atrial flutter only (n = 29), patients with more atrial flutter than AF (n = 22), patients with more AF than atrial flutter (n = 15) and hybrid patients who developed atrial flutter with a class IC drug (n = 16). In general, a low rate of recurrence of AF was observed in this patient population, with the lowest rate in the hybrid patient group. Of the hybrid patients, 73% were free of any recurrence within a 4 ± 2 month follow-up period. First, the authors concluded that linear lesions in the inferior isthmus do not act pro-arrhythmically in terms of creating AF. Second, they stated a potentially beneficial impact of inferior isthmus ablation, because there seemed to be a subgroup of patients in whom the isthmus has a major role to play in the initiation or perpetuation of AF. In a report by Huang and coworkers 4 on 13 patients who converted to either typical or atypical atrial flutter following antiarrhythmic drug treatment, a total of 88.9% of the patients remained in sinus rhythm after successful ablation of the inferior isthmus. In another very interesting report, Philippon et al. 5 studied the risk for recurrence of AF in patients who had atrial flutter as the major clinical problem and AF as a concomitant arrhythmia. In their series of patients, after isthmus ablation of atrial flutter, they observed a recurrence of atrial flutter in 5.9% of the patients and recurrence of AF in 26.4%. According to those investigators, none of the patients were treated with any antiarrhythmic drug. They concluded that linear isthmus ablation does not reduce the risk for AF during follow-up. However, it would be of great interest to know the incidence of AF under drug treatment with propafenone or flecainide.
3 Hybrid therapy for atrial fibrillation H53 Atrial fibrillation Atrial flutter I II III avl avr LA 1/2 LA 3/4 LA 5/6 LA 7/8 LA 9/ RA 1/2 RA 3/4 RA 5/6 RA 7/8 RA 9/10 RA 11/12 RA 13/14 RA 15/16 RA 17/18 RA 19/20 RA 21/22 RA 23/24 HBE 1/2 HBE 3/4 Fig. 2 The recording shows atrial fibrillation with disorganized atrial activation in the right atrium (RA) and left atrium (LA), which converts to typical right atrial flutter with secondary activation of the LA after intravenous administration of disopyramide. HBE=His bundle electrogram. The above-mentioned experience in patients who convert to atrial flutter after administration of a class IC drug suggest that the hybrid approach is very promising for a subgroup of patients with AF. However, there has been only one prospective study in which the true percentage of responders was assessed using a prospective protocol. Stabile et al. 6 tested whether long-term success of hybrid therapy may be predicted by response to flecainide infusion. In 71 consecutive patients with paroxysmal or persistent AF, they demonstrated that patients in whom fibrillation was promoted to atrial flutter by infusion of flecainide 2 mg/kg body weight and who underwent isthmus ablation and oral flecainide treatment have a significantly lower risk for AF during follow-up. Hybrid therapy was superior to oral flecainide only and ablation only. In a retrospective analysis conducted by Riva and coworkers 7 in 305 patients with paroxysmal AF, 14.6% of the patients developed type I atrial flutter with antiarrhythmic drugs. There is a need for prospective studies to provide support for these findings and to add further information about the extent to which the acute effects of flecainide or propafenone, in terms of flutter induction, predicts the long-term behaviour of atrial electrophysiology Pacing and drug treatment Pacing therapy for the prevention of AF has been used clinically and in numerous clinical trials, especially in patients with sick sinus syndrome. Newer studies using bifocal pacing at the coronary sinus orifice or Bachmann s bundle, or stimulation in the distal and proximal coronary sinus aimed at harmonization of atrial repolarization and improvement in inter-atrial conduction times have not yet proven the clinical success of these approaches. 8 In the Pa(3) study, a prospective randomized trial comparing the efficacy of DDDR pacing vs VDD pacing after atrioventricular node ablation in patients with paroxysmal AF, no benefit could be demonstrated for dual chamber rate adaptive (DDDR) pacing vs single chamber ventricular (VDD) pacing, but an increase in AF burden for both groups and a significant number of patients who developed persistent AF during follow-up was shown. This very stringently conducted study emphasizes that pacing alone is not sufficiently effective in reducing arrhythmia burden in patients with paroxysmal AF. Delfaut et al. 9 reported on a series of 30 consecutive patients with bifocal atrial pacing (right atrium and coronary sinus orifice) in whom
4 H54 AF recurrence could be reduced by pacing and additional antiarrhythmic drugs, predominantly class III agents. They stated that the combination of antiarrhythmic drugs and atrial single-site or dual-site pacing should be applied simultaneously to control AF. This is consistent with the experience from other trials, in which dualchamber pacing was not superior to single-chamber pacing with respect to efficacy in preventing AF. There are further ongoing studies assessing the effect of overdrive suppression, anti-extrasystole pacing modes and antitachycardia pacing together with rate smoothing algorithms. Most of these studies are designed to assess the effect without any antiarrhythmic drug. The Atrial Tachyarrhythmia Prevention by Antitachycardia Pacing and Rate Smoothing Therapy (APART) study is an ongoing trial in which 200 patients with a class I pacemaker indication and paroxysmal atrial tachyarrhythmias are randomized to receive preventative pacing and atrial antitachycardia pacing with a beta-blocker (the only allowed concomitant antiarrhythmic drug) and dual chamber (DDD) pacing only. This study will show the effect of pacing alone on the recurrence of atrial arrhythmia and provide an answer as to how many patients need an additional specific antiarrhythmic drug to better control the recurrence of atrial tachyarrhythmia together with pacing features. Combined antiarrhythmic drug use The most commonly used antiarrhythmic drugs for maintaining sinus rhythm in patients with AF are class IC drugs, class III drugs and beta-blockers. However, these drugs are almost always used as a stand-alone therapy. In patients with frequent recurrences of AF and increased sympathoadrenergic tone, the combination of a betablocker and a drug such as flecainide or propafenone may be useful to impact positively on heterotopy and repolarization, and reduce right and left atrial pressure and wall stress. There is no contraindication to combined use in the absence of structural heart disease or reduced left ventricular function, even though combined used is only rarely practiced. The same is true for amiodarone and beta-blockers, which is a combination that may safely be given to patients with an implantable defibrillator but not to patients with lone AF. In the literature there is limited information on the numbers of patients receiving more than one drug at a time for treatment of AF. Pulmonary vein ablation and drugs The most recent approach to the treatment of AF in a subgroup of patients is focal radiofrequency ablation in patients with pulmonary vein ectopy triggering AF The success rate with this new technique is reported to amount to a maximum of 50% in selected patients using different approaches such as focal radiofrequency ablation within the veins, encircling of the veins from within the left atrium, or segmental ablation at the venous orifice. However, Haissaguerre et al. 10 stated that additional antiarrhythmic drug treatment is necessary in many of these patients to increase clinical success. This is attributed especially to extrapulmonary triggers within the left atrium, which are extremely difficult to ablate. Conclusion Because antibradycardia pacing and ablation have not proven to be sufficiently effective when used as a stand-alone therapy in the prevention of AF on a larger scale, combined therapy using these nonpharmacological approaches and antiarrhythmic drugs may be the approach of choice for many patients. One possible way to achieve clinical and symptomatic improvement in a subgroup of patients with AF is a hybrid therapy with a class IC drug and linear isthmus ablation. However, further studies in larger patient populations using this therapeutic approach must be performed to assess the potential benefit of right atrial lesions and antiarrhythmic drugs. Finally, concomitant use of beta-blockers and class IC drugs must be tested with respect to tolerability and safety, because they may represent a promising combination of agents aimed at atrial haemodynamics, excitability and refractoriness, and thus address both initiation and perpetuation of AF. References C. Wolpert et al. 1. Schumacher B, Jung W, Lewalter T, et al. Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation. Am J Cardiol 1999;83: Nabar A, Rodriguez LM, Timmermans C, et al. Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation. Heart 2001;85: Nabar A, Rodriguez LM, Timmermans C, et al. Effect of right atrial isthmus ablation on the occurrence of atrial fibrillation: observations in four patient groups having type I atrial flutter with or without associated atrial fibrillation. Circulation 1999;99:
5 Hybrid therapy for atrial fibrillation H55 4. Huang DT, Monahan KM, Zimetbaum P, et al. Hybrid pharmacologic and ablative therapy: a novel and effective approach for the management of atrial fibrillation. J Cardiovasc Electrophysiol 1998;9: Philippon F, Plump VJ, Epstein AE, et al. The risk of atrial fibrillation following radiofrequency catheter ablation of atrial flutter. Circulation 1995;92: Stabile G, De Simone A, Turco P, et al. Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. J Am Coll Cardiol 2001;37: Riva S, Tondo C, Carbucicchio C, et al. Incidence and clinical significance of transformation of atrial fibrillation to atrial flutter in patients undergoing long-term antiarrhythmic drug treatment. Europace 1999;1: Gillis AM, Connolly SJ, Lacombe P, et al. Randomized crossover comparison of DDDR versus VDD pacing after atrioventricular junction ablation for prevention of atrial fibrillation. The atrial pacing peri-ablation for paroxysmal atrial fibrillation (PA(3)) study investigators. Circulation 2000;102: Delfaut P, Saksena S, Prakash A, et al. Long-term outcome of patients with drug-refractory atrial flutter and fibrillation after single- and dual-site right atrial pacing for arrhythmia prevention. J Am Coll Cardiol 1998;32: Haissaguerre M, Jais P, Shah DC, et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 2000; 101: Gerstenfeld EP, Guerra P, Sparks PB, et al. Clinical outcome after radiofrequency catheter ablation of focal atrial fibrillation triggers. J Cardiovasc Electrophysiol 2001;12: Tsai CF, Tai CT, Hsieh MH, et al. Initiation of atrial fibrillation by ectopic beats originating from the superior vena cava: electrophysiological characteristics and results of radiofrequency ablation. Circulation 2000;102: Pappone C, Rosanio S, Oreto G, et al. Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation 2000;102:
The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It?
The Emerging Atrial Fibrillation Epidemic: Treat It, Leave It or Burn It? Indiana Chapter-ACC 17 th Annual Meeting Indianapolis, Indiana October 19, 2013 Deepak Bhakta MD FACC FACP FAHA FHRS CCDS Associate
More informationTreating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC
Treating AF: The Newest Recommendations Wayne Warnica, MD, FACC, FACP, FRCPC CardioCase presentation Ethel s Case Ethel, 73, presents with rapid heart beating and mild chest discomfort. In the ED, ECG
More informationManagement of Symptomatic Atrial Fibrillation
Management of Symptomatic Atrial Fibrillation John F. MacGregor, MD, FHRS Associate Medical Director, Cardiac Electrophysiology PeaceHealth St. Joseph Medical Center, Bellingham, WA September 18, 2015
More informationAtrial Fibrillation: Drugs, Ablation, or Benign Neglect. Robert Kennedy, MD October 10, 2015
Atrial Fibrillation: Drugs, Ablation, or Benign Neglect Robert Kennedy, MD October 10, 2015 Definitions 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary.
More informationAtrial Fibrillation Cardiac rate control or rhythm control could be the key to AF therapy
Cardiac rate control or rhythm control could be the key to AF therapy Recent studies have proven that an option of pharmacologic and non-pharmacologic therapy is available to patients who suffer from AF.
More informationAblation For Atrial Fibrillation. Bill Petrellis Electrophysiologist
Ablation For Atrial Fibrillation Bill Petrellis Electrophysiologist AF is the most common arrhythmia in the Western world Prevalence 1.1% in Australia conservative estimate - 240,000 June 2009 AF is an
More informationRecurrent AF: Choosing the Right Medication.
In the name of God Shiraz E-Medical Journal Vol. 11, No. 3, July 2010 http://semj.sums.ac.ir/vol11/jul2010/89015.htm Recurrent AF: Choosing the Right Medication. Basamad Z. * Assistant Professor, Department
More informationCOVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION
COVERAGE GUIDANCE: ABLATION FOR ATRIAL FIBRILLATION Question: How should the EGBS Coverage Guidance regarding ablation for atrial fibrillation be applied to the Prioritized List? Question source: Evidence
More informationAtrial Fibrillation and Ablation Therapy: A Patient s Guide
Atrial Fibrillation and Ablation Therapy: A Patient s Guide ATRIAL FIBRILLATION CENTER AT UNIVERSITY OF ROCHESTER MEDICAL CENTER www.heart.urmc.edu 585-275-4775 INTRODUCTION Our goal at the Atrial Fibrillation
More informationHow to control atrial fibrillation in 2013 The ideal patient for a rate control strategy
How to control atrial fibrillation in 2013 The ideal patient for a rate control strategy L. Pison, MD Advances in Cardiac Arrhythmias and Great Innovations in Cardiology - Torino, September 28 th 2013
More informationTreatments to Restore Normal Rhythm
Treatments to Restore Normal Rhythm In many instances when AF causes significant symptoms or is negatively impacting a patient's health, the major goal of treatment is to restore normal rhythm and prevent
More informationPRACTICAL APPROACH TO SVT. Graham C. Wong MD MPH Division of Cardiology Vancouver General Hospital University of British Columbia
PRACTICAL APPROACH TO SVT Graham C. Wong MD MPH Division of Cardiology Vancouver General Hospital University of British Columbia CONDUCTION SYSTEM OF THE HEART SA node His bundle Left bundle AV node Right
More informationTachyarrhythmias (fast heart rhythms)
Patient information factsheet Tachyarrhythmias (fast heart rhythms) The normal electrical system of the heart The heart has its own electrical conduction system. The conduction system sends signals throughout
More informationPresenter Disclosure Information
2:15 3 pm Managing Arrhythmias in Primary Care Presenter Disclosure Information The following relationships exist related to this presentation: Raul Mitrani, MD, FACC, FHRS: Speakers Bureau for Medtronic.
More informationRATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY. Charles Jazra
RATE VERSUS RHYTHM CONTROL OF ATRIAL FIBRILLATION: SPECIAL CONSIDERATION IN ELDERLY Charles Jazra NO CONFLICT OF INTEREST TO DECLARE Relationship Between Atrial Fibrillation and Age Prevalence, percent
More informationCorporate Medical Policy
Corporate Medical Policy Catheter Ablation as a Treatment for Atrial Fibrillation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: catheter_ablation_as_a_treatment_for_atrial_fibrillation
More informationHow do you decide on rate versus rhythm control?
Heart Rhythm Congress 2014 How do you decide on rate versus rhythm control? Dr Ed Duncan Consultant Cardiologist & Electrophysiologist Define Rhythm Control DC Cardioversion Pharmacological AFFIRM study
More information2014: nowadays the one shot technologies and the injectable monitor allow a wide and complete AF patient management. Why shouldn t we use them?
2014: nowadays the one shot technologies and the injectable monitor allow a wide and complete AF patient management. Why shouldn t we use them? Gaetano Senatore DIVISION OF CARDIOLOGY HOSPITAL OF CIRIE
More informationHow should we treat atrial fibrillation in heart failure
Advances in Cardiac Arrhhythmias and Great Innovations in Cardiology Torino, 23/24 Ottobre 2015 How should we treat atrial fibrillation in heart failure Matteo Anselmino Dipartimento Scienze Mediche Città
More informationAtrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI
Atrial Fibrillation and Cardiac Device Therapy RAKESH LATCHAMSETTY, MD DIVISION OF ELECTROPHYSIOLOGY UNIVERSITY OF MICHIGAN HOSPITAL ANN ARBOR, MI Outline Atrial Fibrillation What is it? What are the associated
More informationAtrial Fibrillation An update on diagnosis and management
Dr Arvind Vasudeva Consultant Cardiologist Atrial Fibrillation An update on diagnosis and management Atrial fibrillation (AF) remains the commonest disturbance of cardiac rhythm seen in clinical practice.
More informationAtrial Fibrillation The Basics
Atrial Fibrillation The Basics Family Practice Symposium Tim McAveney, M.D. 10/23/09 Objectives Review the fundamentals of managing afib Discuss the risks for stroke and the indications for anticoagulation
More informationSuccesful Radiofrequency Ablation of Atrial Tachycardia Arising From Within the Coronary Venous Sinus
Succesful Radiofrequency Ablation of Atrial Tachycardia Arising From Within the Coronary Venous Sinus The Harvard community has made this article openly available. Please share how this access benefits
More informationThese guidelines have been withdrawn
These guidelines have been withdrawn MOH clinical practice guidelines are considered withdrawn five years after publication unless otherwise specified in individual guidelines. Users should keep in mind
More informationAtrial fibrillation. Quick reference guide. Issue date: June 2006. The management of atrial fibrillation
Quick reference guide Issue date: June 2006 Atrial fibrillation The management of atrial fibrillation Developed by the National Collaborating Centre for Chronic Conditions Contents Contents Patient-centred
More informationAddendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter
22 July 2010 EMA/CHMP/EWP/213056/2010 Addendum to the Guideline on antiarrhythmics on atrial fibrillation and atrial flutter Draft Agreed by Efficacy Working Party July 2008 Adoption by CHMP for release
More informationAtrial fibrillation (AF) care pathways. for the primary care physicians
Atrial fibrillation (AF) care pathways for the primary care physicians by University of Minnesota Physicians Heart, October, 2011 Evaluation by the primary care physician: 1. Comprehensive history and
More informationATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL)
ATRIAL FIBRILLATION (RATE VS RHYTHM CONTROL) By Prof. Dr. Helmy A. Bakr Mansoura Universirty 2014 AF Classification: Mechanisms of AF : Selected Risk Factors and Biomarkers for AF: WHY AF? 1. Atrial fibrillation
More informationTreatment Strategy for Atrial Fibrillation
Rhythm or rate control in persistent atrial fibrillation Peter G. Guerra, Denis Roy Department of Medicine and Research Center, Montreal Heart Institute, Montreal, Quebec, Canada Selecting appropriate
More informationNgaire has Palpitations
Ngaire has Palpitations David Heaven Cardiac Electrophysiologist/Heart Rhythm Specialist Middlemore, Auckland City and Mercy Hospitals Auckland Heart Group MCQ Ms A is 45, and a healthy marathon runner.
More informationTABLE 1 Clinical Classification of AF. New onset AF (first detected) Paroxysmal (<7 days, mostly < 24 hours)
Clinical Practice Guidelines for the Management of Patients With Atrial Fibrillation Deborah Ritchie RN, MN, Robert S Sheldon MD, PhD Cardiovascular Research Group, University of Calgary, Alberta Partly
More informationPalpitations & AF. Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust
Palpitations & AF Richard Grocott Mason Consultant Cardiologist THH NHS Foundation Trust & Royal Brompton & Harefield NHS Foundation Trust Palpitations Frequent symptom Less than 50% associated with arrhythmia
More informationACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY
Care Pathway Triage category ATRIAL FIBRILLATION PATHWAY ACCIDENT AND EMERGENCY DEPARTMENT/CARDIOLOGY AF/ FLUTTER IS PRIMARY REASON FOR PRESENTATION YES NO ONSET SYMPTOMS OF AF./../ TIME DURATION OF AF
More informationJournal of Clinical and Basic Cardiology
Journal of Clinical and Basic Cardiology An Independent International Scientific Journal Journal of Clinical and Basic Cardiology 2001; 4 (2), 123-129 Petrac D Homepage: www.kup.at/jcbc Online Data Base
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Catheter Ablation as Treatment Page 1 of 29 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Catheter Ablation as Treatment Professional Institutional Original Effective
More informationName of Policy: Transcatheter Ablation of Arrhythmogenic Foci as a Treatment of Atrial Fibrillation
Name of Policy: Transcatheter Ablation of Arrhythmogenic Foci as a Treatment of Atrial Fibrillation Policy #: 283 Latest Review Date: June 2015 Category: Medical Policy Grade: A Background/Definitions:
More informationManaging the Patient with Atrial Fibrillation
Pocket Guide Managing the Patient with Atrial Fibrillation Updated April 2012 Editor Stephen R. Shorofsky, MD, Ph.D. Assistant Editors Anastasios Saliaris, MD Shawn Robinson, MD www.hrsonline.org DEFINITION
More informationDISCLOSURE. Atrial Fibrillation Management An Evidence-based Approach OBJECTIVES BACKGROUND AFFIRM 9/16/2015
Death (%) Mortality (%) 9/16/2015 DISCLOSURE Atrial Fibrillation Management An Evidence-based Approach Jonathon Adams, MD, FHRS Relevant Financial Relationship(s) None Off Label Usage None OBJECTIVES What
More informationSurgeons Role in Atrial Fibrillation
Atrial Fibrillation Surgeons Role in Atrial Fibrillation Steven J Feldhaus, MD, FACS 2015 Cardiac Symposium September 18, 2015 Stages of Atrial Fibrillation Paroxysmal (Intermittent) Persistent (Continuous)
More informationUNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD. Ex parte VINOD SHARMA and DANIEL C. SIGG
UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD Ex parte VINOD SHARMA and DANIEL C. SIGG Appeal 2012-000284 Technology Center 1600 Before ERIC GRIMES, FRANCISCO C. PRATS,
More informationGUIDELINE 11.9 MANAGING ACUTE DYSRHYTHMIAS. (To be read in conjunction with Guideline 11.7 Post-Resuscitation Therapy in Adult Advanced Life Support)
AUSTRALIAN RESUSCITATION COUNCIL GUIDELINE 11.9 MANAGING ACUTE DYSRHYTHMIAS (To be read in conjunction with Guideline 11.7 Post-Resuscitation Therapy in Adult Advanced Life Support) The term cardiac arrhythmia
More informationAtrial Fibrillation: Do We Have A Cure? Raymond Kawasaki, MD AMG Electrophysiology February 21, 2015
Atrial Fibrillation: Do We Have A Cure? Raymond Kawasaki, MD AMG Electrophysiology February 21, 2015 Disclaimer I have no relationships to disclose Do we have a cure for Atrial Fibrillation? The short
More informationSporadic or short episodes of paroxysmal atrial fibrillation - still a need for antithrombotic therapy?
Sporadic or short episodes of paroxysmal atrial fibrillation - still a need for antithrombotic therapy? Carina Blomström Lundqvist Dept Cardiology, Uppsala University, Sweden Patterns of AF Terminates
More informationManagement of Atrial Fibrillation in Heart Failure
Disadvantages of AV Junction Ablation Persistent AFib- no AV synchrony Ongoing risk of thromboembolism Life-long dependency on pacemaker Comparison of LA Ablation vs. AVN Ablation LA Ablation AVN Ablation
More informationCurrent ablation techniques for persistent atrial fibrillation: results of the European Heart Rhythm Association Survey
Europace (215) 17, 1596 16 doi:1.19/europace/euv2 EP WIRE Current techniques for persistent atrial fibrillation: results of the European Heart Rhythm Association Survey Nikolaos Dagres 1 *, Maria Grazia
More informationVisited 9/14/2011. What is Atrial Fibrillation? What you need to know about Atrial Fibrillation. The Normal Heart Rhythm. 1 of 7 9/14/2011 10:50 AM
1 of 7 9/14/2011 10:50 AM Current URL: What you need to know about Atrial Fibrillation What is atrial fibrillation? What causes atrial fibrillation? How is atrial fibrillation diagnosed? What are the dangers
More informationAtrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology
Atrial Fibrillation 2014 How to Treat How to Anticoagulate Allan Anderson, MD, FACC, FAHA Division of Cardiology Projection for Prevalence of Atrial Fibrillation: 5.6 Million by 2050 Projected number of
More informationAtrial Fibrillation Based on ESC Guidelines. Moshe Swissa MD Kaplan Medical Center
Atrial Fibrillation Based on ESC Guidelines Moshe Swissa MD Kaplan Medical Center Epidemiology AF affects 1 2% of the population, and this figure is likely to increase in the next 50 years. AF may long
More informationCardioversion for. Atrial Fibrillation. Your Heart s Electrical System Cardioversion Living with Atrial Fibrillation
Cardioversion for Atrial Fibrillation Your Heart s Electrical System Cardioversion Living with Atrial Fibrillation When You Have Atrial Fibrillation You ve been told you have a heart condition called atrial
More informationDEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services
DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services NEW product from the Medicare Learning Network (MLN) Provider Compliance Tips for Computed Tomography (CT) Scans Podcast,
More informationAtrial Fibrillation Peter Santucci, MD Revised May, 2008
Atrial Fibrillation Peter Santucci, MD Revised May, 2008 Atrial fibrillation (AF) is an irregular, disorganized rhythm characterized by a lack of organized mechanical atrial activity. The atrial rate is
More informationRadiofrequency Ablation for Atrial Fibrillation. A Guide for Adults
Radiofrequency Ablation for Atrial Fibrillation A Guide for Adults Fast Facts n There are different ways to treat atrial fibrillation (A-fib). One kind of treatment involves putting the heart back into
More informationNew in Atrial Fibrillation
New in Atrial Fibrillation September 2011 Stroke prevention more options Rhythm Control -drugs - alternatives to drugs; ablation Rate Control - pace + ablate A-FIB Dell Stroke Risk AFib Two Principles
More informationTraditionally, the goal of atrial fibrillation (AF)
358 Clinical Pharmacist November 2010 Vol 2 Treatment of atrial fibrillation usually involves controlling ventricular rate or restoring sinus rhythm. Equally important is thromboembolic risk assessment
More informationMedical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South
Medical management of CHF: A New Class of Medication Al Timothy, M.D. Cardiovascular Institute of the South Disclosures Speakers Bureau for Amgen Background Chronic systolic congestive heart failure remains
More informationAtrial Fibrillation (AF) March, 2013
Atrial Fibrillation (AF) March, 2013 This handout is meant to help with discussions about the condition, and it is not a complete discussion of AF. We hope it will complement your appointment with one
More informationCatheter Ablation. A Guided Approach for Treating Atrial Arrhythmias
Catheter Ablation A Guided Approach for Treating Atrial Arrhythmias A P A T I E N T H A N D B O O K This brochure will provide an overview of atrial arrhythmias (heart rhythm problems affecting the upper
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF) Key priorities Identification and diagnosis Treatment for persistent AF Treatment for permanent AF Antithrombotic
More informationAtrial Fibrillation Centre
About this guide We have prepared this guide to help you to: learn about atrial fibrillation manage atrial fibrillation and reduce the risk of stroke find out about medicines and other treatment options
More informationElectrocardiographic Issues in Williams Syndrome
Electrocardiographic Issues in Williams Syndrome R. Thomas Collins II, MD Assistant Professor, Pediatrics and Internal Medicine University of Arkansas for Medical Sciences Arkansas Children s Hospital
More informationBasics of Pacing. Ruth Hickling, RN-BSN Tasha Conley, RN-BSN
Basics of Pacing Ruth Hickling, RN-BSN Tasha Conley, RN-BSN The Cardiac Conduction System Cardiac Conduction System Review Normal Conduction Conduction QRS QRS Complex Complex RR PP ST ST segment segment
More informationCatheter Ablation of Arrhythmogenic Foci as Treatment for Atrial Fibrillation
Catheter Ablation of Arrhythmogenic Foci as Treatment for Atrial Fibrillation Policy Number: Original Effective Date: MM.06.011 09/01/2009 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration
More informationWho, when and how to rate control for atrial fibrillation Michiel Rienstra and Isabelle C. Van Gelder
Who, when and how to rate control for atrial fibrillation Michiel Rienstra and Isabelle C. Van Gelder Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen,
More informationDIU de rythmologie et stimulation cardiaque. Orateur : Serge BOVEDA Le 25 janvier 2012
DIU de rythmologie et stimulation cardiaque Titre : Fibrillation atriale paroxystique : ablation, résultats, complications Orateur : Serge BOVEDA Le 25 janvier 2012 Fibrillation Atriale Paroxystique :
More informationGERIATRYCZNE PROBLEMY KLINICZNE/GERIATRICS MEDICAL PROBLEMS
65 G E R I A T R I A 2011; 5: 65-69 GERIATRYCZNE PROBLEMY KLINICZNE/GERIATRICS MEDICAL PROBLEMS Otrzymano/Submitted: 24.02.2011 Poprawiono/Corrected: 01.03.2011 Zaakceptowano/Accepted: 06.03.2011 Akademia
More informationRome, Italy December 4-7, 2012 Rome Cavalieri TIMETABLE
Rome, Italy December 4-7, 2012 Rome Cavalieri Monday, December 3 ROOM Terrazza Monte Mario PATIENT MANAGEMENT CONCEPTS AND CONTROVERSIES IN ELECTROPHYSIOLOGY BIOTRONIK International Fellows Program (IFP)
More information2013 Medicare Physician Coding and Reimbursement Changes
2013 Medicare Physician Coding and Reimbursement Changes Disclaimer This presentation is intended for educational use. Any duplication is prohibited without written consent of Medtronic s Economic Strategies
More informationACLS PHARMACOLOGY 2011 Guidelines
ACLS PHARMACOLOGY 2011 Guidelines ADENOSINE Narrow complex tachycardias or wide complex tachycardias that may be supraventricular in nature. It is effective in treating 90% of the reentry arrhythmias.
More informationCurrent Management of Atrial Fibrillation DISCLOSURES. Heart Beat Anatomy. I have no financial conflicts to disclose
Current Management of Atrial Fibrillation Mary Macklin, MSN, APRN Concord Hospital Cardiac Associates DISCLOSURES I have no financial conflicts to disclose Book Women: Fit at Fifty. A Guide to Living Long.
More informationIntroduction to Electrophysiology. Wm. W. Barrington, MD, FACC University of Pittsburgh Medical Center
Introduction to Electrophysiology Wm. W. Barrington, MD, FACC University of Pittsburgh Medical Center Objectives Indications for EP Study How do we do the study Normal recordings Abnormal Recordings Limitations
More informationAtrial Fibrillation Catheter Ablation versus Surgical Ablation Treatment: FAST A Two-Center Randomized Clinical Trial
Atrial Fibrillation Catheter Ablation versus Surgical Ablation Treatment: FAST A Two-Center Randomized Clinical Trial Lucas Boersma, WimJan van Boven, Alaaddin Yilmaz, Johannes Kelder, Maurits Wijffels
More informationRadiofrequency ablation of atrial tachycardia from no man s land
CASE REPORT 103 A case of atrial tachycardia originating between the His region and the non-coronary cusp Radiofrequency ablation of atrial tachycardia from no man s land Nikola Pavlović a,b, Sven Knecht
More informationCARDIAC ELECTROPHYSIOLOGY, ARRHYTHMIAS AND PACING. Medical Knowledge. Goals and Objectives PF EF MF LF Aspirational
Know the histology and gross anatomy of the normal sinoatrial node, atrial conduction pathways, atrioventricular (AV) junction and nod, His bundle, conduction fascicles and terminal intra-ventricular conduction
More informationPatient Information Sheet Electrophysiological study
Patient Information Sheet Electrophysiological study Your doctor has recommended performing an electrophysiological study (also called EPS). EPS is a diagnostic procedure designed to test and evaluate
More informationHTEC 91. Topic for Today: Atrial Rhythms. NSR with PAC. Nonconducted PAC. Nonconducted PAC. Premature Atrial Contractions (PACs)
HTEC 91 Medical Office Diagnostic Tests Week 4 Topic for Today: Atrial Rhythms PACs: Premature Atrial Contractions PAT: Paroxysmal Atrial Tachycardia AF: Atrial Fibrillation Atrial Flutter Premature Atrial
More informationA randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation
A randomized, controlled trial comparing the efficacy of carvedilol vs. metoprolol in the treatment of atrial fibrillation Gabriel Sayer Lay Abstract: Atrial fibrillation is a common form of irregular,
More informationINFORMATION FOR PATIENTS AND FAMILIES A Patient s Guide to Living with Atrial Fibrillation
INFORMATION FOR PATIENTS AND FAMILIES A Patient s Guide to Living with Atrial Fibrillation 30 Bond Street, Toronto, ON M5B 1W8 Canada 416.864.6060 stmichaelshospital.com Form No. XXXXX Dev. XX/XXXX GOALS
More informationAtrial Fibrillation in the Wolff-Parkinson-White Syndrome. John Whitaker, Conn Sugihara and Michael Cooklin (Guy s and St Thomas NHS Foundation Trust)
Atrial Fibrillation in the Wolff-Parkinson-White Syndrome John Whitaker, Conn Sugihara and Michael Cooklin (Guy s and St Thomas NHS Foundation Trust) A 38 year old paramedic was admitted with symptoms
More informationCardiac Arrhythmias. Introduction. Sinus Rhythms. Premature Beats. Secondary article. John A Kastor, University of Maryland, Baltimore, Maryland, USA
John A Kastor, University of Maryland, Baltimore, Maryland, USA Cardiac arrhythmias are disturbances in the rhythm of the heart manifested by irregularity or by abnormally fast rates ( tachycardias ) or
More informationReimbursement Information For Electrophysiology and Arrhythmia Service Procedures 1
GE Healthcare Information For Electrophysiology and Arrhythmia Procedures 1 2011 Update www.gehealthcare.com/reimbursement This overview addresses coding, coverage, and payment for electrophysiology procedures
More informationHow do you decide on rate versus rhythm control?
How do you decide on rate versus rhythm control? Dr. Mark O Neill Consultant Cardiologist & Electrophysiologist Assumptions Camm et al. EHJ 2010;Sept 25 epub Choice of strategy: Criteria for consideration
More informationThe Decision Tree for Ablation Therapy in Atrial Fibrillation Colin Movsowitz, MD, FACC Cardiology Consultants of Philadelphia Director of Electrophysiology Einstein Medical Center Montgomery Co-Director
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): April 26, 2011 Most Recent Review Date (Revised): January 27, 2015 Effective Date: April 1, 2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationAtrial Fibrillation Management Across the Spectrum of Illness
Disclosures Atrial Fibrillation Management Across the Spectrum of Illness NONE Barbara Birriel, MSN, ACNP-BC, FCCM The Pennsylvania State University Objectives AF Discuss the pathophysiology, diagnosis,
More informationCATHETER ABLATION for ATRIAL FIBRILLATION
CATHETER ABLATION for ATRIAL FIBRILLATION Atrial Fibrillation Clinic Dr. Richard Leather, Dr. Larry Sterns, Dr Paul Novak, Dr. Chris Lane Royal Jubilee Hospital Block 3 rd floor, Rm 343 1952 Bay Street
More informationAtrial Fibrillation : Present Treatment Protocols by Drugs and Interventions
UPDATE ARTICLE JIACM 2003; 4(3): 213-27 Atrial Fibrillation : Present Treatment Protocols by Drugs and Interventions Indranill Basu Ray* Abstract Atrial fibrillation is the commonest arrhythmia encountered
More informationCCAD Training Manual. Cardiac Rhythm Management (CRM)
CCAD Training Manual Cardiac Rhythm Management (CRM) Version 1.0 A D Cunningham 19/3/2008 Introduction This manual is intended to assist users of the Notes Client version of the CCAD Cardiac Rhythm Management
More informationAdding IV Amiodarone to the EMS Algorithm for Cardiac Arrest Due to VF/Pulseless VT
Adding IV Amiodarone to the EMS Algorithm for Cardiac Arrest Due to VF/Pulseless VT Introduction Before the year 2000, the traditional antiarrhythmic agents (lidocaine, bretylium, magnesium sulfate, procainamide,
More informationManagement of Pacing Wires After Cardiac Surgery
Management of Pacing Wires After Cardiac Surgery David E. Lizotte, Jr. PA C, MPAS, FAPACVS President, Association of Physician Assistants in Cardiovascular Surgery Conflicts: None Indications 2008 Journal
More informationMRI Case Study MRI Cervical Spine
MRI Case Study MRI Cervical Spine Jewish Hospital Louisville, KY The Revo MRI SureScan pacing system is MR Conditional designed to allow patients to undergo MRI under the specified conditions for use.
More informationDiagnosis Code Crosswalk : ICD-9-CM to ICD-10-CM Cardiac Rhythm and Heart Failure Diagnoses
Diagnosis Code Crosswalk : to 402.01 Hypertensive heart disease, malignant, with heart failure 402.11 Hypertensive heart disease, benign, with heart failure 402.91 Hypertensive heart disease, unspecified,
More informationElectrophysiology Heart Study - EPS -
Electrophysiology Heart Study - EPS - What is an EPS? EPS is short for ElectroPhysiology heart Study. This procedure looks at the electrical system of your heart. An EPS will show if you have a heart rhythm
More informationAtrial fibrillation (AF) is a common arrhythmia associated
Circumferential Radiofrequency Ablation of Pulmonary Vein Ostia A New Anatomic Approach for Curing Atrial Fibrillation Carlo Pappone, MD, PhD; Salvatore Rosanio, MD, PhD; Giuseppe Oreto, MD; Monica Tocchi,
More informationATRIAL FIBRILLATION (AF) PATIENT INFORMATION
ATRIAL FIBRILLATION (AF) PATIENT INFORMATION The Heart Rhythm Charity Promoting better understanding, diagnosis, treatment and quality of life for individuals with cardiac arrhythmias www.heartrhythmcharity.org.uk
More informationAtrial Fibrillation During an Exploration Class Mission. Mark Lipsett MD, PhD Douglas Hamilton MD, PhD Jay Lemery MD James Polk DO
Atrial Fibrillation During an Exploration Class Mission Mark Lipsett MD, PhD Douglas Hamilton MD, PhD Jay Lemery MD James Polk DO Disclosure Information 82nd Annual Scientific and Human Performance Meeting
More informationArrhythmias Focused Review
My Defibrillator Fired: What to Do? Henry F. Clemo, MD, PhD, FACC, Kenneth A. Ellenbogen, MD, FACC, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia The management of a
More informationA Patient Guide to Atrial Fibrillation and Catheter Ablation
A Patient Guide to Atrial Fibrillation and Catheter Ablation Al-Sabah Arrhythmia Institute 1111 Amsterdam Avenue New York, NY 10025 Phone: 212-523-2400 Fax: 212-523-2571 www.stlukescardiology.org Printed
More informationA focus on atrial fibrillation
A focus on atrial fibrillation Is being female really a risk factor for stroke? Dr Justin Mariani MBBS BMedSci PhD FRACP FCSANZ Consultant Cardiologist and Interventional Heart Failure Specialist Alfred
More informationATRIAL FIBRILLATION: Scope of the Problem. October 2015
ATRIAL FIBRILLATION: Scope of the Problem October 2015 Purpose of the Presentation Review the worldwide incidence and prognosis associated with atrial fibrillation (AF) Identify the types of AF, clinical
More informationAtrial fibrillation. Treatment Guide
Treatment Guide Atrial fibrillation Atrial fibrillation (AF or AFib) is the most common irregular or abnormal heart rhythm disorder, affecting more than 3 million Americans today. Thankfully, more options
More information